Valeo Pharma (TSE:VPH) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Valeo Pharma Inc. has revised its credit agreement with Sagard Healthcare Royalty Partners, extending the due date for an initial $10 million payment and reducing its loan principal by approximately C$6.5 million. The amendment offers Valeo Pharma enhanced financial flexibility to pursue its strategic plans. The company focuses on the commercialization of specialty pharmaceuticals in Canada.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.